All In Biotech

Drug Trial Radar · NCT06488924

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Nov 5, 2024

Primary completion

Apr 30, 2030

Study completion Apr 30, 2030

Sponsor

Lead sponsor
JCR Pharmaceuticals Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.

Conditions

  • Mucopolysaccharidosis III-B

Interventions

  • JR-446Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To establish the safety and tolerability of JR-446 in MPSIIIB patientsTime frame: up to 4 years (multiple visits)
  2. To determine the pharmacodynamic effects of JR-446 in MPSIIIB patientsTime frame: up to 4 years (multiple visits)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hiroshima University Hospital

    Hiroshima, Japan

  • University of the Ryukyus Hospital

    Okinawa, Japan

  • National Center for Child Health and Development

    Tokyo, Japan

  • Mie University Hospital

    Tsu, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.